Rheos Medicines
closedA biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
$60.0m | Series A | ||
| Total Funding | 000k | ||
Related Content
Rheos Medicines is pioneering the field of immunometabolism to develop innovative, precision medicines aimed at treating patients with severe immune-mediated diseases and cancer. The company leverages cutting-edge research to translate insights in immunometabolism into novel therapeutic solutions. Rheos Medicines primarily serves patients suffering from complex immune system disorders and various forms of cancer, operating within the biopharmaceutical market. The business model is centered around research and development, with revenue generated through the commercialization of its proprietary treatments and potential collaborations with other pharmaceutical companies. The company's approach is highly specialized, focusing on the intersection of immunology and metabolism to create targeted therapies that address unmet medical needs.
Keywords: immunometabolism, precision medicines, immune-mediated diseases, cancer, biopharmaceutical, research, development, therapeutic solutions, proprietary treatments, targeted therapies.